MHRA lays out its thinking on AI and medicines regulation
An MHRA document explaining how regulations will adapt to the era of AI and personalised medicine has been well received by the pharma industry.
Newsletters and Deep Dive digital magazine
An MHRA document explaining how regulations will adapt to the era of AI and personalised medicine has been well received by the pharma industry.
Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.
Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.
Asahi Kasei's $920m takeover of Germany's Aicuris in April has paid off with FDA approval for the herpes simplex virus drug at the heart of the deal.
Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks